University of British Columbia - Okanagan
Kelowna, British Columbia, V1V 1V7, Canada
NCT Number: NCT03053713
The Mediterranean Diet Pattern (MDP) has been shown to have beneficial effects on the intestinal bacteria and the immune system in diseases like cancer and diabetes. The aim of this study is to determine if a MDP will have an impact on symptoms, intestinal bacteria and the immune system in Ulcerative Colitis (UC). Symptoms, blood and stool will be examined to determine if the MDP results in changes to the intestinal bacteria or immune system.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Kelowna, British Columbia, V1V 1V7, Canada
Few studies have found a single dietary factor as being protective or detrimental against inflammatory bowel disease (IBD), therefore novel diet approaches for the prevention and treatment of IBD are urgently needed. The Mediterranean Diet Pattern (MDP) is associated with improvements in health status and inflammatory markers in healthy individuals and rodent models of colitis. Reductions in inflammatory biomarkers and a "normalization" of the gut microbiota have been shown in patients with Crohn's disease following a MDP. To date, no studies have examined the effect of MDP on disease activity, inflammatory markers or the effects on the microbiome in ulcerative colitis (UC).
This study will examine the effects of a MDP taken by patients with UC on 1) symptoms, clinical and quality of life endpoints and 2) on gut microbiome and fecal immune biomarkers. One hundred subjects and two subjects with UC will be randomly allocated to follow a MDP for 12 weeks or their usual diet (controls). Upon initiation, throughout and completion of each diet, symptoms, clinical and quality of life endpoints will be monitored. Fecal samples will be collected to assess pH, short-chain fatty acid concentrations, bacterial abundance and diversity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
Time frame: Change from baseline to week 12
The SCCAI is a symptom-based disease activity index that uses six clinical parameters: daytime and nocturnal bowel frequency, urgency, amount of blood in the stool, well-being and extraintestinal manifestations. A reduction of SCCAI >1.5 is considered clinically significant and SCCAI score of <4 is indicative of remission.
Time frame: 12 weeks
Quality of life improvement measured at baseline, week 3, week 6, week 9 and 12.
Time frame: 12 weeks
Fecal microbiota measured by examining microbial taxa from stool at baseline and 12 weeks
Time frame: 12 weeks
Change in mucosal inflammation will be measured by fecal calprotectin at baseline and week 12
Time frame: 12 weeks
Change in markers of inflammation will be measured by serum CRP
Time frame: 12 weeks
Change in markers of inflammation will be measured by serum ferritin
University of British Columbia
Other
The Effect of Diet Modification on Clinical Disease Activity, the Gut Microbiome and Immune Responses in Patients With Ulcerative Colitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03000101
Colitis, Colitis, Ulcerative
Bologna, Italy
View Trial DetailsNCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsNCT04882007
Colitis, Colitis, Ulcerative
Brest, Belarus
View Trial DetailsNCT04060303
Colitis, Colitis, Ulcerative
Chicago, Illinois, United States
View Trial Details